









Markets
/
Stocks
/
nasdaq-stok
/

Stoke Therapeutics Inc

STOK

25.110USD

+2.740+12.25%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

1.38BMarket Cap

34.12P/E TTM



Stoke Therapeutics Inc

25.110

+2.740+12.25%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Stoke Therapeutics Inc

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Stoke Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

49 / 407

Overall Ranking

133 / 4608

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

30.889

Target Price

+38.08%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Stoke Therapeutics Inc Highlights

StrengthsRisks

Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 194.68% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 36.55M.

Overvalued

The company’s latest PE is 35.38, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 65.94M shares, decreasing 2.39% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 3.02K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 8.44, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 10.63M, representing a year-over-year increase of 117.25%, while its net profit experienced a year-over-year increase of 45.09%.

Score

Industry at a Glance

Previous score

8.44

Change



Financials

9.88

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.95

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.13

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Stoke Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 5.39, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 35.38, which is 11.06% below the recent high of 39.29 and 121.86% above the recent low of -7.73.

Score

Industry at a Glance

Previous score

5.39

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 49/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 8.55, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Stoke Therapeutics Inc is 30.00, with a high of 39.00 and a low of 24.00.

Score

Industry at a Glance

Previous score

8.55

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

30.889

Target Price

+38.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Stoke Therapeutics Inc

STOK

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 7.16, which is higher than the Biotechnology & Medical Research industry's average of 6.78. Sideways: Currently, the stock price is trading between the resistance level at 35.76 and the support level at 17.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.87

Change

0.29

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-2.403

Sell

RSI(14)

42.602

Neutral

STOCH(KDJ)(9,3,3)

28.233

Buy

ATR(14)

2.340

High Vlolatility

CCI(14)

-60.031

Neutral

Williams %R

64.676

Sell

TRIX(12,20)

-0.550

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

23.126

Buy

MA10

26.022

Sell

MA20

29.698

Sell

MA50

26.628

Sell

MA100

20.442

Buy

MA200

14.820

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 115.45%, representing a quarter-over-quarter decrease of 0.03%. The largest institutional shareholder is The Vanguard, holding a total of 3.15M shares, representing 5.52% of shares outstanding, with 9.52% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

5.95M

+140.94%

Lynx1 Capital Advisors LLC

5.40M

+2.13%

RTW Investments L.P.

5.12M

Baker Bros. Advisors LP

4.63M

Redmile Group, LLC

4.38M

-2.45%

Morgan Stanley & Co. LLC

3.37M

+4.91%

TD Securities, Inc.

3.17M

The Vanguard Group, Inc.

Star Investors

2.94M

+5.84%

BlackRock Institutional Trust Company, N.A.

2.98M

+5.26%

Marshall Wace LLP

2.30M

+7.92%

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 4.70, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.